Skip to main content
SpringerLink
Log in

A Review of Antihypertensive Drugs and Choosing the Right Antihypertensive for Recurrent Stroke Prevention

  • Chapter
  • First Online:
Book cover Hypertension and Stroke

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

  • 3034 Accesses

Abstract

The etiology of long-standing hypertension is generally multifactorial and very poorly appreciated in the individual patient. Seldom does one drug therapy normalize BP in more than 50 % of patients. Moreover, the initial choice of a medication is often based on nonscientific grounds, anecdotal experience, individual preference, and on occasion intuition. A word-of-mouth approach to therapy sometimes surfaces from successful advertising and/or promotional efforts to both health-care providers and, more recently, patients. These background issues interface with the well-established need for antihypertensive therapy as an important component of secondary stroke reduction and oftentimes unnecessarily confound management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. Stroke. 2003;34:2741–8.

    Article  PubMed  Google Scholar 

  2. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and ischemic attack. Stroke. 2014;45:2160–236.

    Article  PubMed  Google Scholar 

  3. Boan AD, Lackland DT, Ovbiagele B. Lowering of blood pressure for recurrent stroke prevention. Stroke. 2014;45:2506–13.

    Article  PubMed  PubMed Central  Google Scholar 

  4. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A Preliminary result. Chin Med J (Engl). 1995;108:710–7.

    Google Scholar 

  5. PROGRESS Collaborative Group. Randomized trial of a perindopril based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.

    Article  Google Scholar 

  6. Verberk WJ, Kroon AA, Kessels AG, de Leeuw PW. Home blood pressure measurement: a systematic review. J Am Coll Cardiol. 2005;46:743–51.

    Article  PubMed  Google Scholar 

  7. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.

    Article  PubMed  Google Scholar 

  8. O’Brien E, Asmar R, Beilin L, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697–701.

    Article  PubMed  Google Scholar 

  9. Staessen JA, Den Hond E, Celis H, et al. Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: a randomized controlled trial. JAMA. 2004;291:955–64.

    Article  CAS  PubMed  Google Scholar 

  10. Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ. 1988;297:1227–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cruickshank J. The J-curve in hypertension. Curr Cardiol Rep. 2003;5:441–52.

    Article  PubMed  Google Scholar 

  12. Farnett L, Mulrow CD, Linn WD, et al. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which blood pressure reduction is dangerous? JAMA. 1991;265:489–95.

    Article  CAS  PubMed  Google Scholar 

  13. Jansen PA, Gribnau FW, Schulte BP, Pools EF. Contribution of inappropriate treatment for hypertension to pathogenesis of stroke in the elderly. Br Med J. 1986;293:914–7.

    Article  CAS  Google Scholar 

  14. Kannel WB, Wilson PW, Nam BH, et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol. 2004;94:380–4.

    Article  PubMed  Google Scholar 

  15. Lee M, Saver JL, Hong KS, et al. Does achieving an intensive versus usual blood pressure level prevent stroke. Ann Neurol. 2012;71:133–40.

    Article  PubMed  Google Scholar 

  16. Aries MJ, Elting JW, DeKeyser J, et al. Cerebral autoregulation in stroke. Stroke. 2010;41:2697–704.

    Article  PubMed  Google Scholar 

  17. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.

    Article  CAS  PubMed  Google Scholar 

  18. Waldemar G, Ibsen H, Strandgaard S, et al. The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. Am J Hypertens. 1990;3:464–70.

    Article  CAS  PubMed  Google Scholar 

  19. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1303–15.

    Google Scholar 

  20. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–35.

    Article  Google Scholar 

  21. Neal B, MacMahon S, Chapman N. Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials: Blood Pressure Lowering Trialists’ Collaboration. Lancet. 2000;356:1955–64.

    Article  CAS  PubMed  Google Scholar 

  22. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The Cycle Repeats. Drugs. 2002;62:243–62.

    Article  Google Scholar 

  23. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.

    Article  Google Scholar 

  24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  25. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–8.

    Article  CAS  PubMed  Google Scholar 

  26. Messerli FH, Grossman E, Lever AF. Do thiazide diuretics confer specific protection against strokes? Arch Intern Med. 2003;163:2557–660.

    Article  CAS  PubMed  Google Scholar 

  27. Sica DA. Do Pleiotropic effects of antihypertensive medications exist of is it all about the blood pressure. Curr Hypertens Rep. 2008;10:415–20.

    Article  PubMed  Google Scholar 

  28. Bath P. Blood-pressure lowering for the secondary prevention of stroke: ACE inhibition is not the key. Stroke. 2003;34:1334–5.

    Article  PubMed  Google Scholar 

  29. Davis SM, Donnan GA. Blood pressure reduction and ACE inhibition in secondary stroke prevention: mechanism uncertain. Stroke. 2003;34:1335–6.

    Article  PubMed  Google Scholar 

  30. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:1–5.

    Google Scholar 

  31. Sica DA. Pharmacotherapy review: part 2. Angiotensin-receptor blockers. J Clin Hypertens (Greenwich). 2005;7:681–4.

    Article  CAS  Google Scholar 

  32. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int. 2000;58:2084–92.

    Article  CAS  PubMed  Google Scholar 

  33. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  CAS  PubMed  Google Scholar 

  34. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.

    Article  CAS  PubMed  Google Scholar 

  35. Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens (Greenwich). 2005;7 Suppl 1:21–6.

    Article  CAS  Google Scholar 

  36. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340:677–84.

    Article  CAS  PubMed  Google Scholar 

  37. Liu-DeRyke X, Levy PD, Parker D, et al. A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. Neurocrit Care. 2013;19:41–7.

    Article  CAS  PubMed  Google Scholar 

  38. Kuriyama Y, Nakamura M, Kyougoku O, et al. European effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. Eur J Clin Pharmacol. 1990;38:S120–1.

    Article  PubMed  Google Scholar 

  39. Remme WJ, Torp-Pedersen C, Cleland JGF, et al. Carvedilol protects better against vascular events than metoprolol in heart failure. Results from COMET. J Am Coll Cardiol. 2007;49:963–71.

    Article  CAS  PubMed  Google Scholar 

  40. The Dutch TIA Study Group. Trial of secondary prevention with atenolol after transient ischaemic attack or nondisabling ischaemic stroke. Stroke. 1993;24:543–8.

    Article  Google Scholar 

  41. Eriksson S, Olofasson BP, Wester PO. Atenolol in secondary prevention after stroke. Cerebrovasc Dis. 1995;5:21–5.

    Article  Google Scholar 

  42. De Lima LG, Saconato H, Atallah AN, et al. Beta-blockers for preventing stroke recurrence. Cochrane Database Syst Rev. 2014;10, CD007890.

    PubMed  Google Scholar 

  43. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agent: a systematic review and meta-analysis. JAMA. 1997;277:739–45.

    Article  CAS  PubMed  Google Scholar 

  44. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10:23–9.

    Article  CAS  PubMed  Google Scholar 

  45. Parviz Y, Iqbal J, Pitt B, et al. Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends Endocrinol Metab. 2015;26:201–11.

    Article  CAS  PubMed  Google Scholar 

  46. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Expert Opin Pharmacother. 2008;9:625–33.

    Article  CAS  PubMed  Google Scholar 

  47. Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239–46.

    Article  Google Scholar 

  48. Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich). 2005;7:558–62.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, MCV Station, Box 980160, Richmond, VA, 23298-0160, USA

    Domenic A. Sica M.D.

Authors
  1. Domenic A. Sica M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenic A. Sica M.D. .

Editor information

Editors and Affiliations

  1. Departments of Neurological Surgery and Neurology and Neurotherapeutics , University of Texas Southwestern Medical Center , Dallas, Texas, USA

    Venkatesh Aiyagari

  2. Michigan State University Department of Translational Science & Molecular Medicine, Mercy Health Hauenstein Neurosciences, Grand Rapids, Michigan, USA

    Philip B. Gorelick

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sica, D.A. (2016). A Review of Antihypertensive Drugs and Choosing the Right Antihypertensive for Recurrent Stroke Prevention. In: Aiyagari, V., Gorelick, P. (eds) Hypertension and Stroke. Clinical Hypertension and Vascular Diseases. Humana Press, Cham. https://doi.org/10.1007/978-3-319-29152-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29152-9_14

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-29150-5

  • Online ISBN: 978-3-319-29152-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation